How much rapamycin, how often, for how long? A practical 2026 walk-through of the dosing protocols longevity physicians actually use, the trade-offs of each, and how to access the drug off-label.
Rapamycin is the most rigorously validated lifespan-extending drug in animal models. The Interventions Testing Program — a federally funded multi-site protocol that has tested dozens of compounds in genetically heterogeneous mice — has now reproduced rapamycin's lifespan benefit across more than a dozen independent cohorts. No other intervention has come close to that level of replication.
The translation question for humans is no longer "does rapamycin do something interesting at the cellular level?" It does. The questions are practical: at what dose, at what interval, for how long, and with what monitoring. This article summarizes the 2026 state of dosing thinking among the longevity physicians actively prescribing rapamycin off-label, what the human evidence supports, and how patients are obtaining it.
Rapamycin in transplant medicine is dosed daily to maintain trough drug levels that suppress the immune system. That dosing schedule produces well-known side effects — mouth ulcers, hyperlipidemia, glucose intolerance, immunosuppression — and is unsuitable for healthy people seeking healthspan benefits.
The longevity protocol is fundamentally different. It uses intermittent (pulse) dosing — a single oral dose every 7 to 14 days — designed to inhibit mTORC1 (the growth-and-storage complex) without persistently inhibiting mTORC2 (the metabolism-and-glucose complex). Pulse dosing in mice extends lifespan with substantially fewer metabolic side effects than continuous dosing. The clinical observation in humans, while not from randomized longevity outcome trials, is consistent: people on weekly or biweekly pulses tolerate the drug well and rarely report the immunosuppression-related issues seen in transplant patients.
The most common starting protocol. A single 5 mg oral dose taken on the same day each week, fasted (or with a small fat-containing snack to enhance absorption — about 35% bioavailability). This is the protocol used in the PEARL trial, the largest randomized human study of rapamycin for healthspan to date, and the dose most commonly prescribed by physicians in the longevity space who report on their practice.
Tolerability at 5 mg weekly is generally excellent in healthy adults. Mouth ulcers are the most common side effect, typically appearing in the first month and resolving with dose reduction. Lipid changes (modest LDL increase, modest triglyceride increase) appear in a minority of users and usually plateau within 3 months.
Some physicians prefer a longer interval at a slightly higher single dose. The reasoning: a longer washout period gives mTORC2 more time to recover between exposures, theoretically reducing the risk of metabolic side effects, while a higher peak dose may produce a deeper transient mTORC1 inhibition.
Biweekly protocols are particularly common among older users (65+) and those with any history of glucose intolerance. The trade-off is that the cumulative monthly dose is similar to the weekly protocol, but you're betting that pulse depth matters more than pulse frequency.
Newer practitioners are introducing escalation protocols for first-time users. Start at 1 mg weekly for two weeks, increase to 3 mg weekly for two weeks, then 5 mg weekly, finally moving to 8 mg weekly if tolerability allows. The goal is to identify each individual's tolerance ceiling and to acclimate the immune system gradually. Most users settle at 5–6 mg as their long-term maintenance dose.
A subset of practitioners cycle rapamycin — for example, 12 weeks on, 4 weeks off — under the theory that periodic washout periods may preserve insulin sensitivity and immune competence. Cycling is not supported by direct human evidence; the mouse longevity benefit was produced with continuous lifelong intermittent dosing without scheduled breaks. Most prescribing physicians do not cycle, but the option exists and is worth discussing with your physician if you experience side effects.
A common mistake is under-dosing. At 1–2 mg weekly, plasma levels rarely reach the threshold thought to meaningfully inhibit mTORC1 in peripheral tissues. If you're going to take rapamycin, the consensus is to take a dose that has a reasonable chance of working — generally at least 3 mg weekly, with most settling at 5–6 mg weekly.
The PEARL trial used up to 10 mg weekly without serious safety signals over one year, but practical experience suggests that >8 mg weekly increases the rate of side effects without obvious additional benefit. Some published longevity protocols (including Dr. Alan Green's well-known regimen) use 6 mg weekly with a small (~50 mg) dose of grapefruit juice taken simultaneously to inhibit CYP3A4 metabolism and effectively triple the drug's bioavailability — producing peak exposures equivalent to 18 mg without grapefruit. This "rapamycin + grapefruit" approach is controversial and not standard.
Regardless of protocol, baseline and follow-up monitoring is the unequivocal recommendation:
Watch for: lipid elevation >20% from baseline, fasting glucose >100 mg/dL when previously normal, HbA1c trending upward, recurrent mouth sores not resolving with dose reduction, persistent infections.
Rapamycin is FDA-approved as Rapamune (sirolimus), available as a generic, and prescribable off-label by any licensed physician. Three main access pathways:
Conventional primary care or longevity clinic: Bring printed PEARL trial data, the published longevity rationale, and your monitoring labs to a primary care physician open to off-label prescribing. Many will prescribe if the case is well-presented.
Telehealth longevity platforms: Several US-based telehealth platforms now specialize in off-label rapamycin prescribing, including ones specifically focused on healthspan medicine. Expect a clinical evaluation, baseline labs, and a 30-day or 90-day prescription with required follow-up.
Compounding pharmacies: Some compounding pharmacies prepare rapamycin in lower-cost formulations. Always verify FDA-registered 503B status and request third-party potency testing.
For longer-term users, a 90-day supply of generic 1 mg sirolimus tablets typically costs $200–600 with insurance, $400–900 cash. Compounded versions can be cheaper.
Pregnancy, active infection, active cancer treatment (rapamycin is itself an oncology drug — discuss with oncologist), upcoming surgery (stop 1 week prior, restart 2 weeks after), live vaccine within 4 weeks, severe liver or kidney impairment, and people on medications metabolized through CYP3A4 (azole antifungals, certain calcium channel blockers, certain HIV medications) without supervised dose adjustment.
For more on rapamycin's mechanism and the broader case for it, see our overview of rapamycin and mTOR for longevity. For people who can't access rapamycin yet, our companion piece on the best rapamycin alternatives in 2026 covers what compounds reproduce parts of rapamycin's mechanism.
Can I just take rapamycin without a doctor?
No. Rapamycin is a prescription drug with real interactions and side effects. It also requires monitoring. Online sources without prescription are unverified for purity and dose. The legitimate path is a physician relationship.
How long until I notice anything?
Most users notice nothing subjectively. The expected benefits are at the level of biological aging markers and disease prevention over years, not at the level of perceptible energy or recovery. Some users report improved recovery from exercise within 4–8 weeks, but this is not universal.
Will rapamycin make me immunosuppressed?
At pulse dosing, the immunosuppressive effect appears minimal — and there is interesting evidence from the RTB101 trial that intermittent mTOR inhibition may actually *improve* immune function in older adults by clearing senescent immune cells. Avoid rapamycin during active infections.
Is generic sirolimus the same as Rapamune?
Yes. Multiple FDA-approved generics are bioequivalent to brand Rapamune and are the standard for longevity prescribing.